Judith A. Mackall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Judith A. Mackall has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Guilherme F Attizzani
Department of Cardiology, Case Western Reserve University, University Hospitals Cleveland Medical Center , 11100 Euclid Avenue, Lakeside 5038, Cleveland, OH 44106 , USA
2 shared publicationsIvan Cakulev
Center for Cardiac Electrophysiology and Pacing, Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
2 shared publications- Kenneth R. Laurita
Heart and Vascular Research Center, MetroHealth Campus, Case Western Reserve University, Cleveland, Ohio, USA
2 shared publications Sergio G. Thal
Division of Cardiology, Department of Medicine (S.A.-K., F.N., G.F.A., M.A.C., D.I.S., M.S.A., J.A.M., S.G.T.), Case Western Reserve University, Harrington Heart and Vascular Institute, and University Hospitals Cleveland Medical Center, OH
2 shared publicationsShilpkumar Arora
Department of Cardiology, Case Western Reserve University, University Hospitals Cleveland Medical Center , 11100 Euclid Avenue, Lakeside 5038, Cleveland, OH 44106 , USA
2 shared publications- Takahiro Tsushima
Department of Medicine, Division of Cardiology, University Hospitals Harrington Heart & Vascular Institute, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
2 shared publications
Latest Publications
- 6 July 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (2) , e328633
Targeting Late Na + Current: Too Late or Better Late Than Never?
- 6 July 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (2) , e328633
Targeting Late Na + Current: Too Late or Better Late Than Never?
- Open Access
- 2 April 2026
- Published by Elsevier in Heart Rhythm O2
- Vol. 7 (7) , 1257-1258
Vernakalant: Wish you were here
- 2 April 2026
- Published by Elsevier in Heart Rhythm O2
- Vol. 7 (7) , 1257-1258
Open AccessVernakalant: Wish you were here
- Open Access
- 19 February 2026
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 64, 100740
Evaluation of palpitations in pregnancy using an ambulatory event monitor
- 19 February 2026
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 64, 100740
Open AccessEvaluation of palpitations in pregnancy using an ambulatory event monitor
- 1 January 2024
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 17 (1) , e012072
Clinical Management of Brugada Syndrome: Commentary From the Experts
Although there is consensus on the management of patients with Brugada Syndrome with high risk for sudden cardiac arrest, asymptomatic or intermediate-risk patients present clinical management challenges. This document explores the management opinions of experts throughout the world for patients with Brugada Syndrome who do not fit guideline recommendations. Four real-world clinical scenarios were presented with commentary from small expert groups for each case. All authors voted on case-specific questions to evaluate the level of consensus among the entire group in nuanced diagnostic and management decisions relevant to each case. Points of agreement, points of controversy, and gaps in knowledge are highlighted.
- 1 January 2024
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 17 (1) , e012072
Clinical Management of Brugada Syndrome: Commentary From the Experts
Although there is consensus on the management of patients with Brugada Syndrome with high risk for sudden cardiac arrest, asymptomatic or intermediate-risk patients present clinical management challenges. This document explores the management opinions of experts throughout the world for patients with Brugada Syndrome who do not fit guideline recommendations. Four real-world clinical scenarios were presented with commentary from small expert groups for each case. All authors voted on case-specific questions to evaluate the level of consensus among the entire group in nuanced diagnostic and management decisions relevant to each case. Points of agreement, points of controversy, and gaps in knowledge are highlighted.
- Open Access
- 5 May 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (5)
Surgical and transcatheter left atrial appendage closure in patients with atrial fibrillation and hypertrophic cardiomyopathy
Patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF) are at increased stroke risk in comparison to those with non-valvular AF not affected by HCM. To investigate the role of left atrial appendage closure (LAAC) in patients with HCM and AF. We identified patients with HCM and AF using the National Readmission Dataset. Patients were stratified based on LAAC status. The primary efficacy outcome was a composite of ischaemic and haemorrhagic stroke, TIA, and all-cause mortality. The primary safety outcome was a composite of major bleeding and pericardial complications. Patients were matched using inverse probability of treatment weighting. Cox-proportional hazard regression was applied to calculate the hazard ratio (HR) with a 95% confidence interval (CI) on matched cohorts. We identified 71 980 patients with HCM and AF. 1351 (1.9%) patients underwent LAAC. Two hundred and eighty-seven (21.2%) underwent transcatheter LAAC. LAAC was associated with a lower risk of the primary efficacy outcome (2.5% vs. 5.4%, HR: 0.38; 95% CI: 0.17–0.88; P = 0.024), the primary safety outcome (2.9% vs. 6.8%, HR: 0.39; 95% CI: 0.23–0.66, P = 0.001), and reduced major bleeding. The LAAC group trended towards a lower risk of ischaemic stroke and all-cause mortality. Surgical and transcatheter LAAC was associated with a lower risk of haemorrhagic stroke and major bleeding.
- 5 May 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (5)
Open AccessSurgical and transcatheter left atrial appendage closure in patients with atrial fibrillation and hypertrophic cardiomyopathy
Patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF) are at increased stroke risk in comparison to those with non-valvular AF not affected by HCM. To investigate the role of left atrial appendage closure (LAAC) in patients with HCM and AF. We identified patients with HCM and AF using the National Readmission Dataset. Patients were stratified based on LAAC status. The primary efficacy outcome was a composite of ischaemic and haemorrhagic stroke, TIA, and all-cause mortality. The primary safety outcome was a composite of major bleeding and pericardial complications. Patients were matched using inverse probability of treatment weighting. Cox-proportional hazard regression was applied to calculate the hazard ratio (HR) with a 95% confidence interval (CI) on matched cohorts. We identified 71 980 patients with HCM and AF. 1351 (1.9%) patients underwent LAAC. Two hundred and eighty-seven (21.2%) underwent transcatheter LAAC. LAAC was associated with a lower risk of the primary efficacy outcome (2.5% vs. 5.4%, HR: 0.38; 95% CI: 0.17–0.88; P = 0.024), the primary safety outcome (2.9% vs. 6.8%, HR: 0.39; 95% CI: 0.23–0.66, P = 0.001), and reduced major bleeding. The LAAC group trended towards a lower risk of ischaemic stroke and all-cause mortality. Surgical and transcatheter LAAC was associated with a lower risk of haemorrhagic stroke and major bleeding.
- Open Access
- 16 February 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (4) , 1441-1450
Clinical impact of right ventricular pacing burden in patients with post-transcatheter aortic valve replacement permanent pacemaker implantation
Patients who undergo permanent pacemaker (PPM) implantation after transcatheter aortic valve replacement (TAVR) have a worse outcome. The aim of this study was to identify risk factors of worse outcomes in patients with post-TAVR PPM implantation. This is a single-centre, retrospective study of consecutive patients who underwent post-TAVR PPM implantation from 11 March 2011 to 9 November 2019. Clinical outcomes were evaluated by landmark analysis with cut-off at 1 year after the PPM implantation. Of the 1389 patients underwent TAVR during the study duration and a total of 110 patients were included in the final analysis. Right ventricular pacing burden (RVPB) ≥ 30% at 1 year was associated with a higher likelihood of heart failure (HF) readmission [adjusted hazard ratio (aHR): 6.333; 95% confidence interval [CI]: 1.417–28.311; P = 0.016] and composite endpoint of overall death and/or HF (aHR: 2.453; 95% CI: 1.040–5.786; P = 0.040). The RVPB ≥30% at 1 year was associated with higher atrial fibrillation burden (24.1 ± 40.6% vs. 1.2 ± 5.3%; P = 0.013) and a decrease in left ventricular ejection fraction (−5.0 ± 9.8% vs. + 1.1 ± 7.9%; P = 0.005). The predicting factors of the RVPB ≥30% at 1 year were the presence of RVPB ≥40% at 1 month and the valve implantation depth measured from non-coronary cusp ≥4.0 mm (aHR: 57.808; 95% CI: 12.489–267.584; P < 0.001 and aHR: 6.817; 95% CI: 1.829–25.402; P = 0.004). The RVPB ≥30% at 1 year was associated with worse outcomes. Clinical benefit of minimal RV pacing algorithms and biventricular pacing needs to be investigated.
- 16 February 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (4) , 1441-1450
Open AccessClinical impact of right ventricular pacing burden in patients with post-transcatheter aortic valve replacement permanent pacemaker implantation
Patients who undergo permanent pacemaker (PPM) implantation after transcatheter aortic valve replacement (TAVR) have a worse outcome. The aim of this study was to identify risk factors of worse outcomes in patients with post-TAVR PPM implantation. This is a single-centre, retrospective study of consecutive patients who underwent post-TAVR PPM implantation from 11 March 2011 to 9 November 2019. Clinical outcomes were evaluated by landmark analysis with cut-off at 1 year after the PPM implantation. Of the 1389 patients underwent TAVR during the study duration and a total of 110 patients were included in the final analysis. Right ventricular pacing burden (RVPB) ≥ 30% at 1 year was associated with a higher likelihood of heart failure (HF) readmission [adjusted hazard ratio (aHR): 6.333; 95% confidence interval [CI]: 1.417–28.311; P = 0.016] and composite endpoint of overall death and/or HF (aHR: 2.453; 95% CI: 1.040–5.786; P = 0.040). The RVPB ≥30% at 1 year was associated with higher atrial fibrillation burden (24.1 ± 40.6% vs. 1.2 ± 5.3%; P = 0.013) and a decrease in left ventricular ejection fraction (−5.0 ± 9.8% vs. + 1.1 ± 7.9%; P = 0.005). The predicting factors of the RVPB ≥30% at 1 year were the presence of RVPB ≥40% at 1 month and the valve implantation depth measured from non-coronary cusp ≥4.0 mm (aHR: 57.808; 95% CI: 12.489–267.584; P < 0.001 and aHR: 6.817; 95% CI: 1.829–25.402; P = 0.004). The RVPB ≥30% at 1 year was associated with worse outcomes. Clinical benefit of minimal RV pacing algorithms and biventricular pacing needs to be investigated.
- Open Access
- 9 October 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (10) , 1680
Adipogenic Signaling Promotes Arrhythmia Substrates before Structural Abnormalities in TMEM43 ARVC
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic disorder of desmosomal and structural proteins that is characterized by fibro-fatty infiltrate in the ventricles and fatal arrhythmia that can occur early before significant structural abnormalities. Most ARVC mutations interfere with β-catenin–dependent transcription that enhances adipogenesis; however, the mechanistic pathway to arrhythmogenesis is not clear. We hypothesized that adipogenic conditions play an important role in the formation of arrhythmia substrates in ARVC. Cardiac myocyte monolayers co-cultured for 2–4 days with mesenchymal stem cells (MSC) were derived from human-induced pluripotent stem cells with the ARVC5 TMEM43 p.Ser358Leu mutation. The TMEM43 mutation in myocyte co-cultures alone had no significant effect on impulse conduction velocity (CV) or APD. In contrast, when co-cultures were exposed to pro-adipogenic factors for 2–4 days, CV and APD were significantly reduced compared to controls by 49% and 31%, respectively without evidence of adipogenesis. Additionally, these arrhythmia substrates coincided with a significant reduction in IGF-1 expression in MSCs and were mitigated by IGF-1 treatment. These findings suggest that the onset of enhanced adipogenic signaling may be a mechanism of early arrhythmogenesis, which could lead to personalized treatment for arrhythmias associated with TMEM43 and other ARVC mutations.
- 9 October 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (10) , 1680
Open AccessAdipogenic Signaling Promotes Arrhythmia Substrates before Structural Abnormalities in TMEM43 ARVC
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic disorder of desmosomal and structural proteins that is characterized by fibro-fatty infiltrate in the ventricles and fatal arrhythmia that can occur early before significant structural abnormalities. Most ARVC mutations interfere with β-catenin–dependent transcription that enhances adipogenesis; however, the mechanistic pathway to arrhythmogenesis is not clear. We hypothesized that adipogenic conditions play an important role in the formation of arrhythmia substrates in ARVC. Cardiac myocyte monolayers co-cultured for 2–4 days with mesenchymal stem cells (MSC) were derived from human-induced pluripotent stem cells with the ARVC5 TMEM43 p.Ser358Leu mutation. The TMEM43 mutation in myocyte co-cultures alone had no significant effect on impulse conduction velocity (CV) or APD. In contrast, when co-cultures were exposed to pro-adipogenic factors for 2–4 days, CV and APD were significantly reduced compared to controls by 49% and 31%, respectively without evidence of adipogenesis. Additionally, these arrhythmia substrates coincided with a significant reduction in IGF-1 expression in MSCs and were mitigated by IGF-1 treatment. These findings suggest that the onset of enhanced adipogenic signaling may be a mechanism of early arrhythmogenesis, which could lead to personalized treatment for arrhythmias associated with TMEM43 and other ARVC mutations.
- 21 February 2022
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 8 (2) , 222-224
Cardiac Resynchronization Therapy
- 21 February 2022
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 8 (2) , 222-224
Cardiac Resynchronization Therapy
- 1 June 2021
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 7 (6) , 716-718
What Is It About Women?
- 1 June 2021
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 7 (6) , 716-718
What Is It About Women?
- 1 March 2021
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 14 (3) , 370-372
Machine Learning Algorithms for Prediction of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement
- 1 March 2021
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 14 (3) , 370-372
Machine Learning Algorithms for Prediction of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement